Biogeneric Bill Has “Reasonable Chance” In ’07 – Barr; More CEOs Unplugged
• By The Pink Sheet
Barr optimistic about biogenerics in 2007: There is "a reasonable chance for passage" of follow-on biologics legislation in 2007, Barr CEO Bruce Downey says during Morgan Stanley CEOs Unplugged conference in New York Jan. 3. "I would suspect that with the change in the composition of the Congress that we will have hearings on that legislation both in the House and in the Senate," he adds, noting that he expects Rep. Henry Waxman (D-Calif.) to reintroduce follow-on protein legislation during the first two weeks of the new Congress, which was sworn in Jan. 4. Waxman, along with Sens. Chuck Schumer (D-N.Y.) and Hillary Rodham Clinton (D-N.Y.), introduced legislation in October that would grant FDA authority to approve comparable or interchangeable follow-on biologics (1"The Pink Sheet" Oct. 9, 2006, p. 5). If a bill is not passed in 2007, Downey said legislation is unlikely in 2008 due to the presidential election, but he "would certainly expect to see legislation by the end of 2009"...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
The Trump Administration requested a dismissal or transfer of a lawsuit seeking to tighten the safety requirements for the abortion pill mifepristone on procedural grounds, which still leaves the administration's position on the case's merits unclear.
Some advisory committee members said adding quantitative data on misuse, abuse, opioid use disorder and overdose to labeling would be helpful, but others worried the two epidemiological studies were not sufficiently generalizable to a broader population.
Viatris joined Hikma and Amneal, in signing agreements for cash settlements that resolve allegations its practices fueled the US’ deadly opioid epidemic.